Clinical Trial

PathToScale: The PERSIST Trial

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to identify the effectiveness of a bundle of strategies to support continuation of clients on pre-exposure prophylaxis, including long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high priority groups.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-25.
Status change: Not Yet Recruiting → Recruiting 2026-03-02
Trial Details
NCT Number NCT07221747
Lead Sponsor Georgetown University
Collaborators: Center for the Development of People, Centers for Disease Control and Prevention, Elizabeth Glaser Pediatric AIDS Foundation, Healthqual, Johns Hopkins Research Project, Malawi, Johns Hopkins Bloomberg School of Public Health, Blantyre District Health Office, Malawi, Lilongwe District Health Office, Malawi, Lighthouse Trust, Ministry of Health, Malawi, National AIDS Commission, Malawi, Pakachere Institute of Health and Development Communication, Partners in Hope, Inc., University of North Carolina, Chapel Hill, United States President's Emergency Plan for AIDS Relief, Washington University School of Medicine, Clinton Health Access Initiative Inc., Quantitative Engineering Design
Conditions Oral Pre-exposure Prophylaxis (PrEP), Long-acting Injectable Cabotegravir for PrEP
Enrollment 9,900 participants
Start Date 2026-02-16
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-04